Sat, Aug 2, 2014, 5:05 AM EDT - U.S. Markets closed


% | $
Click the to save as a favorite.

Pernix Therapeutics Holdings, Inc. Message Board

zero.risk13 332 posts  |  Last Activity: 16 hours ago Member since: Oct 12, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Now that's a stock!

  • $35M market cap
    An approved product (in the EU, Canada, Mexico....) for a huge market.
    PMA submitted to FDA for US approval.
    First in class patented biophotonics technology.
    A new CEO marketing whiz formerly with Abbott Healthcare and GE Diagnostics.

    Everyhthing is lined up for huge gains.
    Buy now and retire a $millionaire in few years.

  • Reply to

    Consider This

    by zero.risk13 Jul 30, 2014 5:58 PM
    zero.risk13 zero.risk13 Jul 30, 2014 6:29 PM Flag

    Consider this .... a proven and approved potential blockbuster product trumps nothing close to being approved, and at 1/4 the market cap, it's a no brainer; oh brainless wonder.

  • zero.risk13 by zero.risk13 Jul 30, 2014 5:58 PM Flag

    GTHP is now higher priced than ONCS, but the market cap is about 1/4 that of ONCS.

    ONCS will not have anything approved for at least 5 years.
    Considering that small biotechs always get a CRL on their first filing,
    You are probably looking a 7 years and if a P3 trial fails it could be 10 to 12 years.

    GTHP is approved in the EU and several other international markets.
    The PMA was refiled with the FDA a few days ago.
    So approval should come in a few months.

    The HPV testing market is huge.
    Over 60 million pap smear tests are taken annually in the US.
    GTHP has superior technology.
    Biophotonics is more accurate and produces immediate test results.
    Swabs do not need to be sent to a lab.

    Revenues are starting to accelerate.
    The high margin disposables will beef up the profit margins.

    GTHP is on the launch pad.
    ONCS is bobbing on a dangerous sea and could capsize.

  • Reply to

    Merck profits double!

    by ooo_key_doke Jul 29, 2014 8:34 AM
    zero.risk13 zero.risk13 Jul 29, 2014 9:14 AM Flag

    Heck, Merck could buy out GTHP which has an APPROVED product for a multi-billion dollar market in cancer detection. The market cap is only $35M. Why spend over $100M for something that may never be approved?

    It's easy spending other people's money. If you had $200M would you blow it on a P2 long shot or on a company with a product that is producing growing revenues?

  • "Guided Therapeutics, Inc. (GTHP) today announced that it has filed an amendment to its premarket approval (PMA) application with the U.S. Food and Drug Administration (FDA) for the LuViva® Advanced Cervical Scan. The FDA has 180 days to respond to the amendment.

    The company has regulatory approval to sell LuViva in Europe with the Edition 3 CE mark, and has marketing approvals from COFEPRIS in Mexico, Health Canada and Singapore Health Sciences Authority, among others. Additionally, expansion efforts are ongoing in the Middle East, Asia and Latin America."

    GTHP's market cap is $35M and its product is approved internationally and will be approved in the US in a few months.
    ONCS' market cap is $125M and it has nothing approved, is years away from approval, if ever.

    The market is huge for GTHP's biophotonic cervical cancer scan
    Over 60M pap smear tests are taken annually in the US alone.

    "LuViva is a technologically advanced diagnostic device that scans the cervix with light and uses spectroscopy to measure how light interacts with the cervical tissue. Spectroscopy identifies chemical and structural indicators of precancer that may be below the surface of the cervix or misdiagnosed as benign. This technique is called biophotonics. Unlike Pap, HPV tests or biopsies, LuViva does not require laboratory analysis or a tissue sample, and is designed to provide results immediately, which may result in eliminating costly, painful and unnecessary additional testing."

  • Reply to

    A Good Time to Switch to GTHP

    by zero.risk13 Jul 14, 2014 9:42 AM
    zero.risk13 zero.risk13 Jul 17, 2014 4:22 PM Flag

    My GTHP was up today.
    Off to the races on PMA filing this month.

  • Reply to

    GTHP Will Soon Be Higher Priced

    by zero.risk13 Jul 15, 2014 10:17 AM
    zero.risk13 zero.risk13 Jul 16, 2014 1:56 PM Flag

    GTHP is .49, ONCS is .48.

    You are riding the wrong horse.
    Actually, you are riding a broken down nag and I'm riding a stallion.

    Approved always trumps nothing approved for years to come, if ever.

  • Reply to

    GTHP Will Soon Be Higher Priced

    by zero.risk13 Jul 15, 2014 10:17 AM
    zero.risk13 zero.risk13 Jul 15, 2014 11:49 AM Flag

    Almost there.

  • Resubmission of PMA next week = potential 10 bagger.
    International sales are accelerating.
    GTHP is the stock to be in now.

  • Approved beats 'maybe' approved in five years.
    70M shares beats 250M shares.
    .485 beats .574.
    $35M market cap beats $150M market cap.

    Less risk more value.

  • Reply to

    New to OTC

    by lancewerner17 Jul 12, 2014 12:32 AM
    zero.risk13 zero.risk13 Jul 12, 2014 3:29 PM Flag

    Overdiluted stocks are not long term investments.
    AMBS has some 800,000,000 shares outstanding and ONCS has around 300,000,000.
    They are nowhere near approval, so those numbers will increase dramatically.
    You might be able to catch a bounce on one of those stocks for a short term gain, but long term you will get destroyed.

    If you want a potential 10 bagger, GTHP is the stock.
    They have 70M shares outstanding and an approved product on the launch pad for a huge market.
    The cervical cancer scanners are sold for $20K and the disposable used in each scan for about $20.
    The disposable have an 80% to 90% profit margin. (It's like the razor blade business).
    60 million pap smear tests are taken annually in the US.
    That represents a potential $1 billion in profits on the disposables alone in the US.
    The international markets are even larger.

  • zero.risk13 zero.risk13 Jul 11, 2014 8:45 AM Flag

    Seriously? NAVB and EAPH.
    NAVB has overpromised and underdelivered for years. Their debt exceeds their cash and they are burning over $30M annually.
    EAPH is a Canadian penny biotech. Never buy Canadian biotechs.

    Go with a quality undervalued biotech like GTHP.
    Think long term, not just trying to catch a temporary bounce.
    Playing PDUFA dates is foolish gambling.

  • Reply to


    by lopopswz Jul 11, 2014 7:26 AM
    zero.risk13 zero.risk13 Jul 11, 2014 8:27 AM Flag

    Opposing views are good. Why do you want to silence those who differ with your opinion?
    Your post is reeking with sarcasm and chest pounding.
    Do you seriously expect him to respond?

    I always find that the negative posts are more insightful than the self serving pump posts.
    If there is a stock that I am considering buying, I like to read the bearish posts.
    They contain information about management, or competing products or analysis of prior trials
    that is not readily available in company filings.

    Have you ever noticed when some horrid stock craters from $50 to 50 cents, followed by a
    dead dog bounce to $2, there will be pumpers reveling in a 40% or 60% gain instead of
    taking their profit, counting their blessings for catching a fleeting bounce and moving on
    to a quality stock.

    You asked for a stock to buy, here is one: GTHP.
    They have a biophotonic cervical cancer scan that is more accurate than pap smear tests and it produces instant test results.
    Over 60 million pap smear tests are taken annually in the US, so the market opportunity is huge.
    They will be resubmitting the PMA for US approval this month.
    Yesterday they received marketing approval in Mexico.
    The scan is also approved in the EU, Canada, Singapore.....
    International sales are projected to potentially reach $3M this year.
    The new CEO was formerly with Abbott and GE Diagnostics and has vast marketing experience.

    Sales are ramping up and the market cap is only $35M.
    Compare that to a stock with a market cap of $150M with nothing approved.
    Approval is a minimum of five years away, if ever, with only massive dilution to look forward to in the interim.
    Which is the better buy?

  • zero.risk13 by zero.risk13 Jul 10, 2014 5:52 PM Flag

    Chinese stocks always implode.

    GTHP has a biophotonic scan for cervical cancer.
    It will be huge!
    Over 60 million pap smear tests are taken annually in the US alone.
    GTHP' scan is more accurate and produces instant test results.
    They are already approved in the EU, Canada, Mexico, Singapore.....

  • Approved in EU, Canada, Mexico, Singapore
    Resubmission this month for FDA approval.

    Over 60 million pap smear tests are taken annually in the US alone.
    GTHP's biophotonic scan is more accurate and produces instant test results.

    Huge market. Small market cap. = potential 10 bagger this year.

  • Reply to

    O/T Dendreon has many parallels to GALE

    by jrdelane Jul 10, 2014 11:31 AM
    zero.risk13 zero.risk13 Jul 10, 2014 12:04 PM Flag

    DNDN is a disaster.
    Take the $2.30 and roll it over into GTHP.
    Read todays news: their HPV scan was just approved in Mexico (that's in addition to the EU, Canada, Singapore).
    Later this month they are resubmitting for FDA approval.

    GTHP will be a monster stock.
    Over 60 million pap smear tests are taken annually in the US alone.
    GTHP's biophotonic scan is more accurate and produces instant test results.
    Market cap is only $35M.
    Get in on the ground floor!!!!!!!!!!!!!!!!!

  • "Guided Therapeutics, Inc. (GTHP) (GTHP) today announced that LuViva® Advanced Cervical Scan was approved for sale in Mexico by the Federal Commission for Protection against Health Risks (COFEPRIS).

    “Approval to sell LuViva in Mexico is a significant milestone for the company and opens up the second largest market for medical products in Latin America,” said Gene Cartwright, Chief Executive Officer of Guided Therapeutics. “We will be working with Dantien5 Medical, our distributor in Mexico, to promote LuViva for the detection of cervical cancer, a tremendous unmet need in this part of the world.”

    Cervical cancer is the leading cause of cancer in women of reproductive age in Mexico, and remains the second leading cause of cancer deaths in women."

  • HPV testing is a huge market.
    Over 60M pap smear test are taken annually in the US.
    GTHP's biophotonic scan is more accurate and produces instant test results.

    Orders from distributors are flowing in.
    Sales will accelerate in the next few quarters.
    GTHP has 10 bagger potential written all over it.

  • 1/6 the market cap for an APPROVED product for a huge market.
    GTHP's biophotonic scan for cervical cancer is approved in Canada, EU, Singapore .....
    FDA news is expected this week.
    Over 60 million pap smear tests are taken annually in the US.
    GTHP's scan is more accurate and produces instant test results.

    APPROVED for a huge market beats nothing on the horizon .....
    Market cap of only $35M.

6.79-0.72(-9.59%)Aug 1 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.